Pharmaceuticals News and Research

RSS

Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

MAP Pharmaceuticals, Inc. today announced that the Company will present data on LEVADEX (formerly MAP0004), an orally inhaled investigational drug for the acute treatment of migraine, at the 54th Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, CA, June 21-24, 2012.

22 Jun 2012

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.

22 Jun 2012

Study to test NAC and aspirin for people diagnosed with bipolar disorder

A commonly available pharmaceutical drug with anti-inflammatory properties and a nutritional supplement thought to have antioxidant effects are now being tested at The University of Texas Health Science Center at Houston (UTHealth) as add-on therapies for people diagnosed with bipolar disorder.

21 Jun 2012

Congress considers Medicare, FDA proposals

The Senate Finance Committee is once again talking deficit reduction and Medicare as both houses are "poised" to pass an FDA bill.

21 Jun 2012

New understanding of how motor neurons die in spinal muscular atrophy patients

Cedars-Sinai's Regenerative Medicine Institute has pioneered research on how motor-neuron cell-death occurs in patients with spinal muscular atrophy, offering an important clue in identifying potential medicines to treat this leading genetic cause of death in infants and toddlers.

21 Jun 2012

India emerging as model for improvement in developing countries

In this NDTV opinion piece, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, reflects on his recent trip to India, writing, "During my recent visit, I had a chance to see the latest progress on things that matter a lot to us: on eradicating polio and curtailing the spread of infectious diseases like HIV/AIDS and tuberculosis, for example."

21 Jun 2012

Simple new procedure can remove impurities from pharmaceuticals

Scientists are reporting development of a simple new procedure for removing almost 98 percent of an important impurity that can contaminate prescription drugs and potentially increase the risk for adverse health effects in patients.

21 Jun 2012

FDA ODAC votes in favor of Onyx’s Kyprolis

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 with 1 abstention that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis.

21 Jun 2012

Nouveau Life launches Azul Instant supplement for erectile dysfunction

Nouveau Life Pharmaceuticals Inc., a provider of quality all-natural dietary supplements, announced today the release of its Azul Instant supplement.

21 Jun 2012

ePharmaSolutions announces acquisition of Polaris BioPharma Consulting

ePharmaSolutions announces the acquisition of Polaris BioPharma Consulting, a leading global patient recruitment and retention firm headquartered in Slough, UK.

21 Jun 2012

Structure of human P-glycoprotein in a moving 3D computer model

A picture is worth 1,000 words when it comes to understanding how things work, but 3D moving pictures are even better. That's especially true for scientists trying to stop cancer by better understanding the proteins that make some chemotherapies unsuccessful.

21 Jun 2012

UMMS researcher receives Janssen Award for microRNA discovery

Longtime collaborators Victor R. Ambros, PhD, of the University of Massachusetts Medical School (UMMS) and Gary B. Ruvkun, PhD, of Massachusetts General Hospital and Harvard Medical School, were awarded the 2012 Dr. Paul Janssen Award for Biomedical Research today by Johnson & Johnson for their co-discovery of microRNA, tiny molecules that are now understood to play a powerful role in gene expression and regulation.

20 Jun 2012

Supreme Court rules drug firms don't have to pay overtime to sales reps

The 5-4 opinion by Justice Samuel Alito says the sales representatives are not subject to the overtime pay provisions of the Fair Labor Standards Act.

20 Jun 2012

Study identifies critical neurological factor in aggression

Pathological rage can be blocked in mice, researchers have found, suggesting potential new treatments for severe aggression, a widespread trait characterized by sudden violence, explosive outbursts and hostile overreactions to stress.

20 Jun 2012

Theorem Clinical Research introduces new look and tagline

Theorem Clinical Research, a full-service contract research organization (CRO) providing core clinical research and development services, has launched its new look and tagline, "Think Theorem."

20 Jun 2012

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).

20 Jun 2012

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Horizon Pharma, Inc. a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America.

19 Jun 2012

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.

19 Jun 2012

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012